Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
OmniAb, Inc. said it has entered a global collaboration and licensing agreement with Eli Lilly to discover and develop new ion channel therapeutics, a strategy that could validate OmniAb’s technology even as key financial and scientific details remain undisclosed.
THE APEX TIMES
THE APEX TIMES
Eli Lilly (LLY) says the FDA decision broadens Mounjaro’s U.S. use beyond glucose control, adding a heart-risk label that strengthens its competitive position in cardiometabolic care.
THE APEX TIMES
A recent market recap highlights Eli Lilly’s stock outperformance versus the Dow over 12 months and points to continuing Wall Street optimism about the company’s longer-term growth prospects.
THE APEX TIMES
A Yahoo Finance report on Aug. 28 said the company’s weight-loss pipeline received a significant boost from the U.S. Food and Drug Administration, strengthening one of its most important growth areas.
THE APEX TIMES
A Yahoo Finance market note highlighted three reasons to like Eli Lilly, centering on the stock’s recent gains and how they compare with the S&P 500. The post cites a share price around $1,175 and a 15.4% return over six months versus 11.6% for the benchmark.
THE APEX TIMES
A new regulatory acceptance for an oral version of semaglutide in China broadens Novo Nordisk’s potential market in the fast-growing GLP-1 obesity category, but Eli Lilly’s earlier filing suggests its competing pill could arrive first.
THE APEX TIMES
A fresh U.S. Food and Drug Administration approval is set to extend the reach of Mounjaro beyond glucose control, giving Eli Lilly a potential growth pathway in cardiovascular-risk management and raising the stakes for competition in metabolic disease drugs.
THE APEX TIMES
A reported FDA win is putting Eli Lilly’s Mounjaro back at center stage, after data cited in the coverage showed an 8% lower rate of major cardiovascular events compared with Lilly’s own diabetes drug Trulicity.
THE APEX TIMES
Eli Lilly said the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) to lower the risk of major cardiovascular events in adults with type 2 diabetes, extending the obesity-and-diabetes drug’s role beyond glucose control.
